- Raised $308k grant, Nov 2023
- Raised $308k funding round, Mar 2023
- Raised $515k grant, Mar 2023
About
NUTEK takes part in the fight against cancer by pioneering precision in Surgical Oncology. NUTEK is addressing the problem of cancer tissues that remain undetected on the patient's body after surgical intervention, which is the main cause of subsequent cancer recurrence, repeated operations, and aggressive treatments. Furthermore, the resulting economic burden on hospitals, healthcare organizations insurance companies is significantly high.
NUTEK provides a unique intraoperative solution, the "Rainbow Probe". A high-resolution hyperspectral imaging handheld device, by which surgeons will scan the operation cavity on-the-patient’s-body during surgery. The probe guides the surgeon prior to closing, to the exact location of remaining cancer tissue, which otherwise could remain undetected, for immediate removal.
Its first application is Breast Cancer, for which the NOAM Rainbow Probe is developed, to be followed with addressing high-precision and minimally invasive, cancer surgical interventions. .
NUTEK won first prize at Paul Merage Institute startup competition and received a major non-dilutive grant from the FFG (Austrian Innovation Authority) for a two years project. NUTEK is collaborating with the Medical University of Graz in Austria and with Assuta Ashdod Hospital in Israel, completed pre-clinical experiment on breast cancer, developed MVP (TRL6) and designed critical parts of the end-product.
Funding history · 6 rounds · $1.8M total
Q&A
- What is NUTEK OIDO's primary focus?
- NUTEK OIDO is focused on redefining precision in Surgical Oncology, specifically in the on-the-body detection of cancer tissue during operations to prevent recurrence and repeated surgeries.
- What is NUTEK OIDO's key product?
- NUTEK OIDO provides a unique intraoperative solution called the "Rainbow Probe," a high-resolution hyperspectral imaging handheld device that guides surgeons to remaining cancer tissue for immediate removal during surgery.
- What is the initial application of the NOAM Rainbow Probe?
- The NOAM Rainbow Probe's first application is for Breast Cancer, with plans to address other high-precision and minimally invasive cancer surgical interventions in the future.
- How much funding has NUTEK OIDO raised in total?
- NUTEK OIDO has raised a total of $1,781,000 USD across multiple funding rounds.
- When did NUTEK OIDO receive its most recent grant funding?
- In November 2023, NUTEK OIDO received a grant of $308,000 USD.
- Which organizations have provided grant funding to NUTEK OIDO?
- NUTEK OIDO has received grant funding from organizations including Merage Institute, European Space Agency Business Incubator, and FFG - Austrian Federal Innovation Authority.
- How many employees does NUTEK OIDO have?
- NUTEK OIDO has 1-10 employees.
- Where is NUTEK OIDO headquartered?
- NUTEK OIDO is headquartered in Rishon LeTsiyon, Israel, and also has an office in Graz, Austria.
- Who are the co-founders of NUTEK OIDO?
- The co-founders of NUTEK OIDO are Dov Cohen (Co-founder & CEO), Ofer Braun (Co-founder & CTO), and Prof. MD. Hanoch Kashtan (Co-founder, Medical Director).
Team · 3
Sectors & technology
Highlights
Tags
Full data — links, identifiers, deals & radar signals (jobs, patents, research, more)
External links
| Website | nutekmedtech.com |
|---|---|
| linkedin.com/in/dov-cohen-68b7a783/ |
Identifiers & details
| Founded | 2019-6 |
|---|---|
| Employees (exact) | 7 |
| Offices | Graz |
Radar intelligence
Web history (Wayback)
| Domain | nutekmedtech.com |
|---|
Certificate / subdomain footprint
| Subdomains | 3 |
|---|